Platelet-derived chemokines: Pathophysiology and therapeutic aspects

Cellular and Molecular Life Sciences

Volumn 67, Issue 14, 2010, Pages 2363-2386

  Flad, Hans Dieter ^a   Brandt, Ernst ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

Author keywords

Angiogenesis; Chemokines; Host defense; Pathophysiology; Platelets; Therap; Thrombocidins; Thrombocytopoiesis

Indexed keywords

APLAVIROC; CHEMOKINE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; CXCL3 CHEMOKINE; CXCL9 CHEMOKINE; DF 2156A; EOTAXIN; FINGOLIMOD; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 8; LENTIVIRUS VECTOR; MAB 004; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MARAVIROC; MONOCLONAL ANTIBODY; N ACETYLPROLYLGLYCYLPROLINE; PLERIXAFOR; PRO 140; RANTES; RIBOZYME; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC; CHEMOKINE RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTERIOSCLEROSIS; ASTHMA; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BRAIN ISCHEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; DRUG TOLERABILITY; HEMATOPOIESIS; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MICROBIAL IMMUNITY; MONOCYTE; MULTIPLE SCLEROSIS; NEUTROPHIL; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; RNA INTERFERENCE; T LYMPHOCYTE ACTIVATION; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; TUMOR VASCULARIZATION; ANGIOGENESIS; ANIMAL; CHEMOTAXIS; DRUG ANTAGONISM; HOMEOSTASIS; HYPERSENSITIVITY; IMMUNOLOGY; INFECTION; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NEUTROPHIL CHEMOTAXIS; PHYSIOLOGY; THROMBOCYTE; THROMBOCYTOPOIESIS;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; CHEMOKINES; CHEMOTAXIS; HOMEOSTASIS; HUMANS; HYPERSENSITIVITY; INFECTION; INFLAMMATION; MONOCYTES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; NEUTROPHIL INFILTRATION; RECEPTORS, CHEMOKINE; THROMBOPOIESIS;

EID: 77954602114     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-010-0306-x     Document Type: Review

References (226)

1. Weyrich AS, Zimmerman GA (2004) Platelets: signaling cells in the immune continuum. Trends Immunol 25:489-495
2. Elzey BD, Tian J, Jensen RJ, Swanson AK, Lees JR, Lentz SR, Stein CS, Nieswandt B, Wang Y, Davidson BL, Ratliff TL (2003) Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity 19:9-19
3. Otterdal K, Smith C, Oie E, Pedersen TM, Yndestad A, Stang E, Endresen K, Solum NO, Aukrust P, Damas JK (2006) Plateletderived LIGHT induces inflammatory responses in endothelial cells and monocytes. Blood 108:928-935
4. Klinger MH, Wilhelm D, Bubel S, Sticherling M, Schroder JM, Kuhnel W (1995) Immunocytochemical localization of the chemokines RANTES and MIP-1 alpha within human platelets and their release during storage. Int Arch Allergy Immunol 107:541-546
5. Power CA, Clemetson JM, Clemetson KJ, Wells TN (1995) Chemokine and chemokine receptor mRNA expression in human platelets. Cytokine 7:479-482
6. Brandt E, Ludwig A, Petersen F, Flad HD (2000) Plateletderived CXC chemokines: old players in new games. Immunol Rev 177:204-216
7. Weber C (2005) Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 96:612-616
8. El Golli N, Issertial O, Rosa JP, Broquet-Laugier V (2005) Evidence for a granule targeting sequence within platelet factor 4. J Biol Chem 280:30329-30335
9. Walz A, Dewald B, von Tscharner V, Baggiolini M (1989) Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils. J Exp Med 170:1745-1750
10. Walz A, Baggiolini M (1989) A novel cleavage product of betathromboglobulin formed in cultures of stimulated mononuclear cells activates human neutrophils. Biochem Biophys Res Commun 159:969-975
11. 2+]i changes and respiratory burst in human neutrophils and monocytes induced by NAP-1/interleukin-8, NAP-2, and gro/MGSA. J Leukoc Biol 50:279-286
12. Yan Z, Zhang J, Holt JC, Stewart GJ, Niewiearowski S, Poncz M (1994) Structural requirements of platelet chemokines for neutrophil activation. Blood 84:2329-2339
13. Clark-Lewis I, Dewald B, Loetscher M, Moser B, Baggiolini M (1994) Structural requirements for interleukin-8 function identified by design of analogs and CXC chemokine hybrids. J Biol Chem 269:16075-16081
14. Petersen F, Flad HD, Brandt E (1994) Neutrophil-activating peptides NAP-2 and IL-8 bind to the same sites on neutrophils but interact in different ways. Discrepancies in binding affinties, receptor densities, and biologic effects. J Immunol 152:2467-2478
15. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B (1994) Both interleukin-8 receptors independently mediate chemotaxis. Jurkat cells transfected with IL-8R1 or IL-8R2 migrate in response to IL-8, GRO alpha and NAP-2. FEBS Lett 341:187-192
16. Ahuja SK, Murphy PM (1996) The CXC chemokines growthrelated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the typeA, human interleukin-8 receptor. J Biol Chem 271:20545-20550
17. Clark-Lewis I, Dewald B, Geiser T, Moser B, Baggiolini M (1993) Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg. Proc Natl Acad Sci USA 90:3574-3577
18. Petersen F, Ludwig A, Flad HD, Brandt E (1996) TNF-alpha renders human neutrophils responsive to platelet factor 4. Comparison of PF-4 and IL-8 reveals different activity profiles of the two chemokines. J Immunol 156:1954-1962
19. Fleischer J, Grage-Griebenow E, Kasper B, Heine H, Ernst M, Brandt E, Flad HD, Petersen F (2002) Platelet factor 4 inhibits proliferation and cytokine release of activated human T cells. J Immunol 169:770-777
20. Pervushina O, Scheuerer B, Reiling N, Behnke L, Schroder JM, Kasper B, Brandt E, Bulfone-Paus S, Petersen F (2004) Platelet factor 4/CXCL4 induces phagocytosis and the generation of reactive oxygen metabolites in mononuclear phagocytes independently of Gi protein activation or intracellular calcium transients. J Immunol 173:2060-2067
21. Petersen F, Bock L, Flad HD, Brandt E (1998) A chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation. J Immunol 161:4347-4355
22. Kasper B, Brandt E, Bulfone-Paus S, Petersen F (2004) Platelet factor 4 (PF-4)-induced neutrophil adhesion is controlled by srckinases while PF-4-mediated exocytosis requires the additional activation of p38 MAP kinase and phosphatidylinositol 3-kinase. Blood 103:1602-1610
23. Kasper B, Brandt E, Ernst M, Petersen F (2006) Neutrophil adhesion to endothelial cells induced by platelet factor 4 requires sequential activation of Ras, Syk, and JNK MAP kinases. Blood 107:1768-1775
24. Mueller A, Meiser A, McDonagh EM, Fox JM, Petit GX, Williams TJ, Pease JM (2008) CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3. J Leukoc Biol 83:875-882
25. Schall TJ, Greaves DR (2000) RANTES/CCL5. In: Oppenheim JJ, Feldman M (eds.-in-chief), Durum SK, Hirano T, Vilcek J, Nicola NA (eds) Cytokine reference. A Compendium of cytokines and other mediators of host defense, vol 1: ligands. Academic Press, London, pp 1161-1166
26. Schall TJ, Bacon K, Toy KJ, Goeddel DV (1990) Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 347:669-671
27. Taub DD, Lloyd ER, Wang JM, Oppenheim JJ, Kelvin DJ (1993) The effects of human recombinant MIP-1 alpha, MIP-1 beta, and RANTES on the chemotaxis and adhesion of T cell subsets. Adv Exp Med Biol 351:139-146
28. Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, Dahinden CA (1992) RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granules. J Exp Med 176:1489-1495
29. Kameyoshi Y, Dörschner A, Mallet AI, Christophers E, Schrö-der JM (1992) Cytokine RANTES released by thrombinstimulated platelets is a potent attractant for human eosinophils. J Exp Med 176:587-592
30. Kuna P, Reddigari SR, Schall TJ, Rucinski D, Viksman MY, Kaplan AP (1992) RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils. J Immunol 49:636-642
31. 2+ mobilization, and enzyme release. J Immunol 156:322-327
32. Sozzani S, Luini W, Borsatti A, Polentarutti N, Zhou D, Piemonti L, D́Amico G, Power CA, Wells TN, Gobbi M, Allavena P, Mantovani A (1997) Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J Immunol 159:1993-2000
33. Brandt E, Van Damme J, Flad HD (1991) Neutrophils can generate their activator neutrophil-activating peptide 2 by proteolytic cleavage of platelet-derived connective tissue-activating peptide III. Cytokine 3:311-321
34. Walz A, Baggiolini M (1990) Generation of the neutrophilactivating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases. J Exp Med 171:449-454
35. Begg GS, Pepper DS, Chesterman CN, Morgan FJ (1978) Complete covalent structure of human beta-thromboglobulin. Biochemistry 17:1739-1744
36. Holt JC, Rabellino EM, Gewirtz AM, Gunkel LM, Rucinski B, Niewiarowski S (1988) Occurrence of platelet basic protein, a precursor of low affinity platelet factor 4 and beta-thromboglobulin, in human platelets and megakaryocytes. Exp Hematol 16:302-306
37. Majumdar S, Gonder D, Koutsis B, Poncz M (1991) Characterization of the human beta-thromboglobulin gene. Comparison with the gene for platelet factor 4. J Biol Chem 266:5785-5789
38. Zhang C, Gadue P, Scott E, Atchison M, Poncz M (1997) Activation of the megakaryocyte-specific gene platelet basic protein (PBP) by the Ets family factor PU.1. J Biol Chem 272:26236-26246
39. Harter L, Petersen F, Flad HD, Brandt E (1994) Connective tissue-activating peptide III desensitizes chemokine receptors on neutrophils. Requirement for proteolytic formation of the neutrophil-activating peptide 2. J Immunol 153:5698-5708
40. Car BD, Baggiolini M, Walz A (1991) Formation of neutrophilactivating peptide 2 from platelet-derived connective-tissueactivating peptide III by different tissue proteinases. Biochem J 275:581-584
41. Malkowski MG, Lazar JB, Johnson PH, Edwards BF (1997) The amino-terminal residues in the crystal structure of connective tissue activating peptide-III (des10) block the ELR chemotactic sequence. J Mol Biol 266:367-380
42. Campbell EJ, Senior RM, McDonald JA, Cox DL (1982) Proteolysis by neutrophils. Relative importance of cell-substrate contact and oxidative inactivation of proteinase inhibitors in vitro. J Clin Invest 70:845-852
43. Travis J, Salvesen GS (1983) Human plasma proteinase inhibitors. Annu Rev Biochem 52:655-709
44. Schiemann F, Grimm TA, Hoch J, Gross R, Lindner B, Petersen F, Bulfone-Paus S, Brandt E (2006) Mast cells and neutrophils proteolytically activate chemokine precursor CTAP-III and are subject to counterregulation by PF-4 through inhibition of chymase and cathepsin G. Blood 107:2234-2242
45. Schenk BI, Petersen F, Flad HD, Brandt E (2002) Plateletderived chemokines CXC chemokine ligand (CXCL)7, CTAPIII, and CXCL4 differentially affect and cross-regulate neutrophil adhesion and transendothelial migration. J Immunol 169:2602-2610
46. Petersen F, Bock L, Flad HD, Brandt E (1999) Platelet factor 4-induced neutrophil-endothelial cell interaction: involvement of mechanisms and functional consequences different from those elicited by interleukin-8. Blood 94:4020-4028
47. Baltus T, von Hundelshausen P, Mause SF, Buhre W, Rossaint R, Weber C (2005) Differential and additive effects of plateletderived chemokines on monocyte arrest under flow conditions. J Leukoc Biol 78:435-441
48. Mause SF, von Hundelshausen P, Zernecke A, Koenen RR, Weber C (2005) Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol 25:1512-1518
49. Mack M, Pfirstinger J, Weber C, Weber KS, Nelson PJ, Rupp T, Maletz K, Brühl H, Schlöndorff D (2002) Chondroitin sulfate A released from platelets blocks RANTES presentation on cell surfaces and RANTES-dependent firm adhesion of leukocytes. Eur J Immunol 32:1012-1020
50. von Hundelshausen P, Koenen RR, Sack M, Mause SF, Adriaens W, Proudfoot AE, Hackeng TM, Weber C (2005) Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 105:924-930
51. Baltus T, Weber KS, Johnson Z, Proudfoot AE, Weber C (2003) Oligomerization of RANTES is required for CCR1-mediated arrest but not CCR5-mediated transmigration of leukocytes on inflamed endothelium. Blood 102:1985-1988
52. Clemetson KJ, Clemetson JM, Proudfoot AE, Power CA, Baggiolini M, Wells TN (2000) Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood 96:4046-4054
53. Abi-Younes S, Sauty A, Mach F, Sukhova GK, Libby P, Luster AD (2000) The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res 86:131-138
54. Abi-Younes S, Si-Tahar M, Luster AD (2001) The CC chemokines MDC and TARC induce platelet activation via CCR4. Thromb Res 101:279-289
55. Gear AR, Suttitanamongkol S, Viisoreanu D, Polanowska-Grabowska RK, Raha S, Camerini D (2001) Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function. Blood 97:937-945
56. Suttitanamongkol S, Gear AR (2001) ADP receptor antagonists inhibit platelet aggregation induced by the chemokines SDF-1, MDC and TARC. FEBS Lett 490:84-87
57. Coleman LG Jr, Polanowska-Grabowska RK, Marcinkiewicz M, Gear AR (2004) LDL oxidized by hypochlorous acid causes irreversible platelet aggregation when combined with low levels of ADP, thrombin, or macrophage-derived chemokine (CCL22). Blood 104:380-389
58. Shenkman B, Brill A, Brill G, Lider O, Savion N, Varon D (2004) Differential response of platelets to chemokines: RANTES non-competitively inhibits stimulatory effect of SDF-1 alpha. J Thromb Haemost 2:154-160
59. Han ZC, Bellucci S, Tenza D, Caen JP (1990) Negative regulation of human megakaryocytopoiesis by human platelet factor 4 and beta thromboglobulin: comparative analysis in bone marrow cultures from normal individuals and patients with essential thrombocythaemia and immune thrombocytopenic purpura. Br J Haematol 74:395-401
60. Han ZC, Bellucci S, Walz A, Baggiolini M, Caen JP (1990) Negative regulation of human megakaryocytopoiesis by human platelet factor 4 (PF4) and connective tissue-activating peptide (CTAP-III). Int J Cell Cloning 8:253-259
61. Gewirtz AM, Zhang J, Ratajczak J, Ratajczak M, Park KS, Li C, Yan Z, Poncz M (1995) Chemokine regulation of human megakaryocytopoiesis. Blood 86:2559-2567
62. Emadi S, Clay D, Desterke C, Guerton B, Maquarre E, Charpentier A, Jasmin C, Le Bousse-Kerdilès MC (2005) IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis. Blood 105:464-473
63. Deutsch V, Bitan M, Friedmann Y, Eldor A, Vlodavsky I (2000) Megakaryocyte maturation is associated with expression of the CXC chemokine connective tissue-activating peptide CTAP III. Br J Haematol 111:1180-1189
64. Oda M, Kurasawa Y, Todokoro K, Nagata Y (2003) Thrombopoietin-induced CXC chemokines, NAP-2 and PF4, suppress polyploidization and proplatelet formation during megakaryocyte maturation. Genes Cells 8:9-15
65. Wang JF, Liu ZY, Groopman JE (1998) The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitors to platelets and modulates migration and adhesion. Blood 92:756-764
66. Hamada T, Möhle R, Hesselgesser J, Hoxie J, Nachman RL, Moore MA, Rafii S (1998) Transendothelial migration of megakaryocytes in response to stromal cell-derived factor 1 (SDF-1) enhances platelet formation. J Exp Med 188:539-548
67. Kowalska MA, Ratajczak J, Hoxie J, Brass LF, Gewirtz A, Poncz M, Ratajczak MZ (1999) Megakaryocyte precursors, megakaryocytes and platelets express the HIV co-receptor CXCR4 on their surface: determination of response to stromalderived factor-1 by megakaryocytes and platelets. Br J Haematol 104:220-229
68. Berthebaud M, Riviere C, Jarrier P, Foudi A, Zhang Y, Compagno D, Galy A, Vainchenker W, Louache F (2005) RGS16 is a negative regulator of SDF-1-CXCR4 signaling in megakaryocytes. Blood 106:2962-2968
69. Secchiero P, Celeghini C, Cutroneo G, Baldassarre Di, Rana R, Zauli G (2000) Differential effects of stromal derived factor-1 alpha (SDF-1 alpha) on early and late stages of human megakaryocytic development. Anat Rec 260:141-147
70. Hodohara K, Fujii N, Yamamoto N, Kaushansky K (2000) Stromal cell-derived factor-1 (SDF-1) acts together with thrombopoietin to enhance the development of megakaryocytic progenitor cells (CFU-MK). Blood 95:769-775
71. Majka M, Janowska-Wieczorek A, Ratajczak J, Kowalska MA, Vilaire G, Pan ZK, Honczarenko M, Marquez LA, Poncz M, Ratajczak MZ (2000) Stromal-derived factor 1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis. Blood 96:4142-4151
72. Maassberg S, Konrad I, Schürzinger K, Lorenz M, Schneider S, Zohlnhoefer D, Hoppe K, Schiemann M, Kennerknecht E, Sauer S, Schulz C, Kerstan S, Rudelius M, Seidl S, Sorge F, Langer H, Peluso M, Goyal P, Vestweber D, Emambokus NR, Busch DH, Frampton J, Gawaz M (2006) Platelets secrete stromal cellderived factor1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med 203:1221-1233
73. Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, Anver MR, Kleinman HK, Murphy WJ, Oppenheim JJ (1999) Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromalderived factor-1alpha. Am J Pathol 154:1125-1135
74. Petit I, Jin D, Rafii S (2007) The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 28:299-307
75. Hristov M, Zernecke A, Bidzhekov K, Liehn EA, Shagdarsuren E, Ludwig A, Weber C (2007) Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res 100:590-597
76. Schober A, Manka D, von Hundelshausen P, Huo Y, Hanrath P, Sarembock IJ, Ley K, Weber C (2002) Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 106:1523-1529
77. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Mariott D, Chan SY, Roczniak S, Shanafelt AB (1995) The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270:27348-27357
78. Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, Buechi L, Walz A, Richmond A, Strieter RM (2000) The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+CXC chemokine-induced angiogenic activity. J Immunol 165:5269-5277
79. Belperio JA, Keane MP, Burdick MD, Gomperts B, Xue YY, Hong K, Mestas J, Ardehali A, Mehrad B, Saggar R, Lynch JP, Ross DJ, Strieter RM (2005) Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. J Clin Invest 115:1150-1162
80. Brill A, Elinav H, Varon D (2004) Differential role of platelet granular mediators in angiogenesis. Cardiovasc Res 63:226-235
81. Maione TE, Gray GS, Petro J, Donner AL, Bauer SI, Carson HF, Sharpe RJ (1990) Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247:77-79
82. Watson JB, Getzler SB, Mosher DF (1994) Platelet factor 4 modulates the mitogenic activity of basic fibroblast growth factor. J Clin Invest 94:261-268
83. Gentilini G, Kirschbaum NE, Augustine JA, Aster RH, Visentin GP (1999) Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (PF4), is associated with impaired downregulation of p21(Cip1/WAF1). Blood 93:25-33
84. Luster AD, Greenberg SM, Leder P (1995) The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 182:219-231
85. Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M, Uguccioni M, Galli G, Cosmi L, Maurenzi L, Baggiolini M, Maggi E, Romagnani S, Serio M (2001) Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 107:53-63
86. Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA (1997) Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med 3:437-442
87. Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, Taub DT, Iannettoni MD, Whyte RI, Strieter RM (1996) Interferon-c-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 184:981-992
88. Vandercappellen J, Van Damme J, Struyf S (2008) The role of CXC chemokines and their receptors in cancer. Cancer Lett 28:226-244
89. Yang J, Richmond A (2004) The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol Ther 9:846-855
90. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P (2003) An alternatively spliced variant of CXCR3 mediates the the inhibition of endothelial cell growth induced by IP-10, Mig, and I-Tac and acts as functional receptor for platelet factor 4. J Exp Med 197:1537-1549
91. Struyf S, Burdick MD, Peeters E, Van den Broeck K, Dillen C, Proost P, Van Damme J, Strieter RM (2007) Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res 67:5940-5948
92. Gengrinovitch S, Greenberg SM, Cohen T, Gitary-Goren H, Rockwell P, Maione TE, Levi BZ, Neufeld G (1995) Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. J Biol Chem 270:15059-15065
93. Perollet C, Han ZC, Savona C, Caen JP, Bikfalvi A (1998) Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood 91:3289-3299
94. Sulpice E, Contreres JO, Lacour J, Bryckaert M, Tobelem G (2004) Platelet factor 4 disrupts the intracellular signalling cascade induced by vascular endothelial growth factor by both KDR dependent and independent mechanisms. Eur J Biochem 271:3310-3318
95. Aidoudi S, Bujakowska K, Kieffer N, Bikfalvi A (2008) The CXC chemokine CXCL4 interacts with integrins implicated in angiogenesis. PloS ONE 3:e2657
96. Green CJ, Charles RS, Edwards BF, Johnson PH (1989) Identification and characterization of PF4var1, a human gene variant of platelet factor 4. Mol Cell Biol 9:1445-1451
97. Struyf S, Burdick MD, Proost P, Van Damme J, Strieter RM (2004) Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ Res 95:855-857
98. Yeaman MR, Tang YQ, Shen AJ, Bayer AS, Selsted ME (1997) Purification and in vitro activities of rabbit platelet microbicidal proteins. Infect Immun 65:1023-1031
99. Yeaman MR, Yount NY, Waring AJ, Gank KD, Kupferwasser D, Wiese R, Bayer AS, Welch WH (2007) Modular determinants of antimicrobial activity in platelet factor-4 family kinocidins. Biochim Biophys Acta 1768:609-619
100. Krijgsveld J, Zaat SAJ, Meeldijk J, van Veelen PA, Fang G, Poolman B, Brandt E, Ehlert J, Kuijpers AJ, Engbers GHM, Feijen J, Dankert J (2000) Thrombocidins, microbicidal proteins from human blood platelets, are C-terminal deletion products of CXC chemokines. J Biol Chem 275:20374-20381
101. Tang YQ, Yeaman MR, Selsted ME (2002) Antimicrobial peptides from human platelets. Infect Immun 70:6524-6533
102. Nakayama T, Shirane J, Hieshima K, Shibano M, Watanabe M, Jin Z, Nagakubo D, Saito T, Shimomura Y, Yoshie O (2006) Novel antiviral activity of chemokines. Virology 350:484-492
103. Yeaman MR, Bayer AS, Koo SP, Foss W, Sullam PM (1998) Platelet microbicidal proteins and neutrophil defensin disrupt the Staphylococcus aureus cytoplasmic membrane by distinct mechanisms of action. J Clin Invest 101:178-187
104. Iida N, Haisa M, Igarashi A, Pencev D, Grotendorst GR (1996) Leukocyte-derived growth factor links the PDGF and CXC chemokine families of peptides. FASEB J 10:1336-1345
105. Pillai MM, Iwata M, Awaya N, Graf L, Torok-Storb B (2006) Monocyte-derived CXCL7 peptides in the marrow microenvironment. Blood 107:3520-3526
106. El-Gedaily A, Schoedon G, Schneemann M, Schaffner A (2004) Constitutive and regulated expression of platelet basic protein in human monocytes. J Leukoc Biol 75:495-503
107. Schaffner A, King CC, Schaer D, Guiney DG (2004) Induction and antimicrobial activity of platelet basic protein derivatives in human monocytes. J Leukoc Biol 76:1010-1018
108. Schaffner A, Rhyn P, Schoedon G, Schaer DJ (2005) Regulated expression of platelet factor 4 in human monocytes-role of PARs as a quantitatively important monocyte activation pathway. J Leukoc Biol 78:202-209
109. Khajoee V, Saito M, Takada H, Nomura A, Kusuhara K, Yoshida SI, Yoshikai Y, Hara T (2006) Novel roles of osteopontin and CXC chemokine ligand 7 in the defence against mycobacterial infection. Clin Exp Immunol 143:260-268
110. Kruidenier L, MacDonald TT, Collins JE, Pender SL, Sanderson IR (2006) Myofibroblast matrix metalloproteinases activate the neutrophil chemoattractant CXCL7 from intestinal epithelial cells. Gastroenterology 130:127-136
111. Nakao K, Aoyama M, Fukuoka H, Fujita M, Miyazawa K, Asai K, Goto S (2009) IGF2 modulates the microenvironment for osteoclastogenesis. Biochem Biophys Res Commun 378:462-466
112. Vandercapellen J, Noppen S, Verbeke H, Put W, Conings R, Gouwy M, Schutyser E, Proost P, Sciot R, Geboes K, Opdenakker G, Damme Van, Struyf S (2007) Stimulation of angiostatic platelet factor-4 variant (CXCL4L1/PF-4var) versus inhibition of angiogenic granulocyte chemotactic protein 2 (CXCL6/GCP-2) in normal and tumoral mesenchymal cells. J Leukoc Biol 82:1519-1530
113. Lasagni L, Grepin R, Mazzinghi B, Lazzeri E, Meini C, Sagrinati C, Liotta F, Frosali F, Ronconi E, Alain-Courtois N, Ballerini L, Netti GS, Maggi E, Annunziato F, Serio M, Romagnani S, Bikfalvi A, Romagnani P (2007) PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion. Blood 109:4127-4134
114. Auten RL, Richardson RM, White JR, Mason SN, Vozzelli MA, Whorton MH (2001) Nonpeptide CXCR2 antagonist prevent neutrophil accumulation in hypoxia-exposed newborn rats. J Pharmacol Exp Ther 299:90-95
115. Matzer SP, Zombou J, Sarau HM, Röllinghoff M, Beuscher HU (2004) A synthetic, non-peptide CXCR2 antagonist blocks MIP-2-induced neutrophil migration in mice. Immunobiology 209:225-233
116. Garau A, Bertini R, Mosca M, Bizzarri C, Anacardio R, Triulzi S, Allegretti M, Ghezzi P, Villa P (2006) Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat. Eur Cytokine Netw 17:35-41
117. Singh S, Sadanandam A, Nannuru KC, Varney ML, Mayer-Ezell R, Bond R, Singh RK (2009) Small molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival and angiogenesis. Clin Cancer Res 15:2380-2386
118. Kerstetter AE, Padovani-Claudio DA, Bai L, Miller RH (2009) Inhibition of CXCR2 signaling promotes recovery in models of multiple sclerosis. Exp Neurol 120:44-56
119. Chapman RW, Phillips JE, Hipkin RW, Curran AK, Lundell D, Fine JS (2009) CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 121:55-68
120. Zarbock A, Allegretti M, Ley K (2008) Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice. Br J Pharmacol 155:357-364
121. Johnson Z, Schwarz M, Power CA, Wells TN, Proudfoot AE (2005) Multi-faceted strategies to combat disease by interference with the chemokine system. Trends Immunol 26:268-274
122. Ford SL, Reddy YS, Anderson MT, Murray SC, Fernandez P, Stein DS, Johnson MA (2006) Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 50:2201-2206
123. Westby M, van der Ryst E (2005) CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antiviral Chem Chemother 16:339-354
124. De Clercq E (2003) The bicyclam AMD3100 story. Nat Rev Drug Discov 2:581-587
125. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M (2005) Maraviroc (UK427857), a potent bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49:4721-4752
126. Fätkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins TM, Medhurst C, Sullivan JF, Ridgway C, Abel S, James IT, Youle M, van der Ryst E (2005) Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist. Nat Med 11:1170-1172
127. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, Dorr P, Ciaramella G, Perros M (2007) Reduced maximal inhibition in phenotypic susceptibility assays indicate that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 81:2359-2571
128. Schürmann D, Fätkenheuer G, Reynes J, Michelet C, Raffi F, van Lier J, Caceres M, Keung A, Sansone-Parsons A, Dunkle LM, Hoffmann C (2007) Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 21:1295-1299
129. Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik R, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DR, AIDS Clinical Trials Group 5211 Team (2007) Phase 2 Study of the safety and efficacy of Vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS Clinical Trial Group 5211. J Infect Dis 196:304-312
130. Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM (2007) HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. J Clin Infect Dis 44:591-595
131. Murga JD, Franti M, Pevear DC, Maddon PJ, Olson W (2006) Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob Agents Chemother 50:3289-3296
132. Ji C, Zhang J, Dioszegi M, Chiu S, Rao E, Derosier A, Cammack N, Brandt M, Sankuratri S (2007) CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by co-binding to the receptor. Mol Pharmacol 72:18-28
133. Strayer DS, Akkina R, Bunnell BA, Dropulic B, Planelles V, Pomerantz RJ, Rossi JJ, Zaia JA (2005) Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther 11:823-842
134. Swan CH, Torbett BE (2006) Can gene delivery close the door to HIV-1 entry after escape? J Med Primatol 11:236-247
135. Luis Abad J, Gonzalez MA, del Real G, Mira E, Manes S, Serrano F, Bernad A (2003) Novel interfering bifunctional molecules against CCR5 coreceptor are efficient inhibitors of HIV infection. Mol Ther 8:478-484
136. Swan CH, Buhler B, Tschan MP, Barbas CF, Torbett BE (2006) T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther 13:1480-1492
137. Bai J, Sui J, Zhu RY, Tallarico AS, Gennari F, Zhang D, Marasco WA (2003) Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J Biol Chem 278:1433-1442
138. Fox JL (2007) Antivirals become a broader enterprise. Nat Biotechnol 25:1395-1402
139. Salvucci O, Yao L, Villalba S, Sajewicz A, Pittaluga S, Tosato G (2002) Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood 99:2703-2711
140. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, Bosch-Marce M, Masuda H, Losordo DW, Isner JM, Asahara T (2003) Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularisation. Circulation 107:1322-1328
141. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancerrelated inflammation. Nature 254:436-444
142. Mikami S, Nakase H, Yamamoto S, Takeda Y, Yoshino T, Kasahara K, Ueno S, Uza N, Oishi S, Fujii N, Nagasawa T, Chiba TJ (2008) Blockade of CXCL12/CXCR4 axis ameliorates murine experimental colitis. Pharmacol Exp Ther 327:383-392
143. Tsutsumi H, Tanaka T, Ohashi N, Masuno H, Tamamura H, Hiramatsu K, Araki T, Ueda S, Oishi S, Fujii N (2006) Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents. Biopolymers 88:279-289
144. Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, Young LM, Hooper AT, Amano H, Avecilla ST, Heissig B, Hattori K, Zhang F, Hicklin DJ, Wu Y, Zhu Z, Dunn A, Salari H, Werb Z, Hackett NR, Crystal RG, Lyden D, Rafii S (2006) Cytokinemediated deployment of SDF-1 induces revascularization through recruitment of CXCR+ hemangiocytes. Nat Med 12:557-567
145. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Chimenti S, Landsman L, Abramovitch R, Keshet E (2006) VEGF-induced adult neovascularisation: recruitment, retention, and role of accessory cells. Cell 124:175-189
146. Redjal N, Chan JA, Segal RA, Kung AL (2006) CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res 12:6765-6771
147. Ohki Y, Heissig B, Sato Y, Akiyama H, Zhu Z, Hicklin DJ, Shimada K, Ogawa H, Daida H, Hattori K, Ohsaka A (2005) Granulocyte colony-stimulating factor promotes neovascularisation by releasing vascular endothelial growth factor from neutrophils. FASEB J 19:2005-2007
148. Körbling M, Reuben JM, Gao H, Lee BN, Harris DM, Cogdell D, Giralt SA, Khouri IF, Saliba RM, Champlin RE, Zhang W, Estrov Z (2006) Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis. Transfusion 46:1795-1802
149. Misao Y, Takemura G, Arai M, Ohno T, Onogi H, Takahashi T, Minatoguchi S, Fujiwara T, Fujiwara H (2006) Importance of recruitment of bone-marrow-derived CXCR4+ cells in postinfarct cardiac repair mediated by G-CSF. Cardiovasc Res 71:455-465
150. Kovacic JC, Muller DW, Graham RM (2007) Actions and therapeutic potential of G-CSF and GM-CSF in cardiovascular disease. J Mol Cell Cardiol 42:19-33
151. Luyt CE, Meddahi-Pellé A, Ho-Tin-Noe B, Colliec-Jouault S, Guezennec J, Louedec L, Prats H, Jacob MP, Osborne-Pellegrin M, Letourneur D, Michel JB (2003) Low-molecular-weight fucoidan promotes therapeutic revascularization in a rat model of critical hindlimb ischemia. J Pharmacol Exp Ther 305:24-30
152. Zhong R, Law P, Wong D, Merzouk A, Salari H, Ball ED (2004) Small peptide analogs to stromal-derived factor-1 enhance chemotactic migration of human and mouse hematopoietic cells. Exp Hematol 32:470-475
153. Walter DH, Rochwalsky U, Reinhold J, Seeger F, Aicher A, Urbich C, Spyridopoulos I, Chun J, Brinkmann V, Keul P, Levkau B, Zeiher AM, Dimmeler S, Haendeler J (2007) Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signalling pathway via the S1p3 receptor. Arterioscler Thromb Vasc Biol 27:275-282
154. Ratajczak MZ, Reca R, Wysoczynski M, Yan J, Ratajczak J (2006) Modulation of the SDF-1-CXCR4+ axis by the third complement component (C3)-implications for trafficking of CXCR4+ stem cells. Exp Hematol 34:986-995
155. Schober A, Karshovska E, Zernecke A, Weber C (2006) SDF-1 alpha-mediated tissue repair by stem cells: a promising tool in cardiovascular medicine? Trends Cardiovasc Med 16:103-108
156. Proudfoot AE (2002) Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2:106-115
157. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, Buser R, Wells TN, Proudfoot AE (1997) Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276:276-279
158. Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M, Piatak M Jr, Lifson JD, Salkowitz JR, Rodriguez B, Blauvelt A, Hartley O (2004) Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306:485-487
159. Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I (1997) An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in MRL-lpr mouse model. J Exp Med 186:131-137
160. Ludwig A, Ehlert JE, Flad HD, Brandt E (2000) Identification of distinct surface-expressed and intracellular CXC chemokine receptor 2 glycoforms in neutrophils: N-glycosylation is essential for maintenance of receptor surface expression. J Immunol 165:1044-1052
161. Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, Borlat F, Wells TN, Kosco-Vilbois MH (2003) Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 100:1885-1890
162. Johnson Z, Kosco-Vilbois MH, Herren S, Cirillo R, Muzio V, Zaratin P, Carbonatto M, Mack M, Smailbegovic A, Rose M, Lever R, Page C, Wells TN, Proudfoot AE (2004) Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J Immunol 173:5776-5785
163. Netelenbos T, van den Born J, Kessler FL, Zweegman S, Merle PA, van Oostveen JW, Zwaginga JJ, Huijgens PC, Dräger AM (2003) Proteoglycans on bone marrow endothelial cells bind and present SDF-1 towards hematopoietic cells. Leukemia 17:175-184
164. Weathington NM, van Houvelingen AH, Noerager BD, Jackson PL, Kraneveld AD, Galin FS, Folkerts G, Nijkamp FP, Blalock JE (2006) A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med 12:317-323
165. Ure DR, Lane TE, Liu MT, Rodriguez M (2005) Neutralization of chemokines RANTES and MIG increases virus antigen expression and spinal cord pathology during Theileŕs virus infection. Int Immunol 17:569-579
166. Mahler DA, Huang S, Tabrizi M, Bell GM (2004) Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 126:926-934
167. Dar A, Goichberg P, Shinder V, Kalinkovich A, Kollet O, Netzer N, Margalit R, Zsak M, Nagler A, Hardan I, Resnick I, Rot A, Lapidot T (2005) Chemokine receptor CXCR4-dependent internalisation and resecretion of functional chemokine SDF-1 by bone marrow endothelial and stromal cells. Nat Immunol 6:1038-1146
168. Middleton J, Neil S, Wintle J, Clark-Lewis I, Moore H, Lam C, Auer M, Hub E, Rot A (1997) Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 91:385-395
169. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10:858-864
170. Kollet O, Shivtiel S, Chen YQ, Suriawinata J, Thung SN, Dabeva MD, Kahn J, Spiegel A, Dar A, Samira S, Goichberg P, Kalinkovich A, Arenzana-Seisdedos F, Nagler A, Hardan I, Revel M, Shafritz DA, Lapidot T (2003) HGF, SDF-1 and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. J Clin Invest 112:160-169
171. Ponomaryov T, Peled A, Petit I, Taichman RS, Habler L, Sandbank J, Arenzana-Seisdedos F, Magerus A, Caruz A, Fujii N, Nagler A, Lahav M, Szyper-Kravitz M, Zipori D, Lapidot T (2000) Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function J. Clin Invest 106:1331-1339
172. Reichert JM (2007) Trends in the development and approval of monoclonal antibodies for viral infections. BioDrugs 21:1-7
173. Mehrad B, Keane MP, Strieter RM (2007) Chemokines as mediators of angiogenesis. Thromb Haemost 97:755-762
174. Keane MP, Arenberg DA, Lynch JP 3rd, Whyte RI, Iannettoni MD, Burdick MD, Wilke CA, Morris SB, Glass MC, DiGiovine B, Kunkel SL, Strieter RM (1997) The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 159:1437-1443
175. Keane MP, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue YY, Strieter RM (1999) IFN-gamma-inducible protein-10 atenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 163:5686-5692
176. Keane MP, Belperio JA, Moore TA, Moore BB, Arenberg DA, Smith RE, Burdick MD, Kunkel SL, Strieter RM (1999) Neutralization of the CXC chemokine macrophage inflammatory protein-2 attenuates bleomycin-induced pulmonary fibrosis. J Immunol 162:5511-5518
177. Keane MP, Donelly SC, Belperio JA, Goodman RB, Dy M, Burdick MD, Fishbein MC, Strieter RM (2002) Imbalance in the expression of CXC chemokines correlates with bronchoalveolar lavage fluid angiogenic activity and procollagen levels in acute respiratory distress syndrome. J Immunol 169:6515-6521
178. Pan J, Burdick MD, Belperio JA, Xue YY, Gerard C, Sharma S, Dubinett SM, Strieter RM (2006) CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J Immunol 176:1456-1464
179. Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX, Batra RK, Dubinett SM (2000) Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 164:4558-4563
180. Sharma S, Yang SC, Hillinger S, Zhu LX, Huang M, Batra RK, Lin JF, Burdick MD, Strieter RM, Dubinett SM (2003) SLC/ CCL21-mediated anti-tumor responses require IFN-gamma, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer 2:22
181. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, Pittet MJ (2007) Ly 6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 117:195-205
182. Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, Garin A, Liu J, Mack M, van Rooijen N, Lira SA, Habenicht AJ, Randolph GJ (2007) Monocyte subsets differentially employ CCR2, CCR5, and CX3 CR1 to accumulate within artherosclerotic plaques. J Clin Invest 117:185-194
183. Kovanen PT (2007) Mast cells: multipotent local effector cells in atherothrombosis. Immunol Rev 217:105-122
184. Davi G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357:2482-2494
185. Llodrá J, Angeli V, Liu J, Trogan E, Fisher EA, Randolph GJ (2004) Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive plaques. Proc Natl Acad Sci USA 101:11779-11784
186. Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, Tacke F, Randolph GJ, Fisher EA (2006) Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci USA 103:3781-3786
187. Eisenberg SP, Evans RJ, Arend WP, Verderber E, Brewer MT, Hannum CH, Thompson RC (1990) Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 343:341-346
188. Seckinger P, Isaaz S, Dayer JM (1988) A human inhibitor of tumor necrosis factor alpha. J Exp Med 167:1511-1516
189. Novick D, Cohen B, Tal N, Rubinstein M (1995) Soluble and membrane-anchored forms of the human IFN alpha/beta receptor. J Leukoc Biol 57:712-718
190. Novick D, Kim H, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M (1999) Interleukin-18 binding protein: a novel modulator of the TH1 cytokine response. Immunity 10:127-136
191. Murphy PM, Baggiolini M, Charo IF, Hébert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA (2000) International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52:145-176
192. Dawson TC, Lentsch AB, Wang Z, Cowhig JE, Rot A, Maeda N, Peiper SC (2000) Exaggerated response to endotoxin in mice lacking the Duffy antigen receptor for chemokines (DARC). Blood 96:1681-1684
193. Luo H, Chaudhuri A, Zbrzezna V, He Y, Pogo AO (2000) Deletion of murine Duffy gene (Dfy) reveils that the Duffy receptor is functionally redundant. Mol Cell Biol 20:3091-3101
194. Du J, Luan J, Liu H, Daniel TO, Peiper S, Chen TS, Yu Y, Horton LW, Nanney LB, Strieter RM, Richmond A (2002) Potential role for Duffy antigen chemokine-binding protein in angiogenesis and maintenance of homeostasis in response to stress. J Leukoc Biol 71:41-53
195. Shen H, Schuster R, Stringer KF, Waltz SE, Lentsch AB (2006) The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth. FASEB J 20:59-64
196. Lee JS, Frevert CW, Thorning DR, Segerer S, Alpers CE, Cartron JP, Colin Y, Wong VA, Martin TR, Goodman RB (2003) Enhanced expression of Duffy antigen in the lungs during suppurative pneumonia. J Histochem Cytochem 51:159-166
197. Nibbs RJ, Kriehuber E, Ponath PD, Parent D, Qin S, Campbell JD, Henderson A, Kerjaschki D, Maurer D, Graham GJ, Rot A (2001) The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors. Am J Path 158:867-877
198. McKimmie CS, Fraser AR, Hansell C, Gutiérrez L, Philipsen S, Connell L, Rot A, Kurowska-Stolarska M, Carreno P, Pruenster M, Chu CC, Lombardi G, Halsey C, McInnes IB, Liew FY, Nibbs RJ, Graham GJ (2008) Hemopoietic cell expression of the chemokine decoy receptor D6 is dynamic and regulated by GATA1. J Immunol 181:3353-3363 (Erratum in: J Immunol 181, 8170. Corrected and republished in: J Immunol 181, 8171-8181)
199. Frau AM, Locati M, Otero K, Sironi M, Signorelli P, Massardi ML, Gobbi M, Vecchi A, Sozzani S, Mantovani A (2003) Cutting edge: scavenging of inflammatory CC chemokines by the promiscuous putatively silent chemokine receptor D6. J Immunol 170:2279-2282
200. Nibbs RJ, Graham G, Rot A (2003) Chemokines on the move: control by the chemokine "interceptors" Duffy blood group antigen and D6. Semin Immunol 15:287-294
201. Jamieson T, Cook DN, Nibbs RJ, Rot A, Nixon C, McLean P, Alcami A, Lira SA, Wiekowski M, Graham GJ (2005) The chemokine receptor D6 limits the inflammatory response in vivo. Nat Immunol 6:403-411
202. Bowcock AM, Shannon W, Du F, Duncan J, Cao K, Aftergut K, Catier J, Fernandez-Vina MA, Menter A (2001) Insights into psoriasis and other inflammatory diseases from large scale gene expression studies. Hum Mol Genet 10:1793-1805
203. Nibbs RJ, Yang J, Landau NR, Mao JH, Graham GJ (1999) LD78beta, a non-allelic variant of human MIP1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity. J Biol Chem 274:17478-17483
204. Proost P, Mahieu F, Schutyser E, Van Damme J (2004) Posttranslational processing of chemokines. Meth Mol Biol 239:27-44
205. Proost P, Menten P, Struyf S, Schutyser E, De Meester I, Van Damme J (2000) Cleavage by CD26//dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist. Blood 96:1674-1680
206. Ludwig A, Petersen F, Zahn S, Götze O, Schröder JM, Flad HD, Brandt E (1997) The chemokine neutrophil-activating peptide-2 induces two distinct optima of neutrophil chemotaxis by differential interaction with interleukin-8 receptors CXCR1 and CXCR2. Blood 90:4588-4597
207. Jones SA, Wolf M, Qin S, Mackay CR, Baggiolini M (1996) Different functions for the interleukin 8 receptors (IL-8R) of human leukocytes: NADPH oxidase and phospholipase D are activated through IL-8R1 but not IL-8R2. Proc Natl Acad Sci USA 93:6682-6686
208. Hartl D, Latzin P, Hordijk P, Marcos V, Rudolph C, Woischnik M, Krauss-Etschmann S, Koller B, Reinhardt D, Roscher AA, Roos D, Griese M (2007) Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 13:1423-1430
209. Bianchi ME (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81:1-5
210. Bianchi SM, Prince LR, McPhillips K, Allen L, Marriott HM, Taylor GW, Hellewell PG, Sabroe I, Dockrell DH, Henson PW, Whyte MK (2008) Impairment of apoptotic cell engulfment by pyocyanin, a toxic metabolite of Pseudomonas aeruginosa. Am J Respir Crit Care Med 177:35-43
211. Alcami A (2003) Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol 3:36-50
212. De Bruyne LA, Li K, Bishop DK, Bromberg JS (2000) Gene transfer of virally encoded chemokine antagonists vMIP-II and MC 148 prolongs cardiac allograft survival and inhibits donorspecific immunity. Gene Ther 7:575-582
213. Aliberti J, Valenzuela JG, Carruthers VB, Hieny S, Andersen J, Charest H, Reis, e Sousa C, Fairlamb A, Ribeiro JM, Sher A (2003) Molecular mimicry of a CCR5 binding-domain in the microbial activation of dendritic cells. Nat Immunol 4:485-490
214. Golding H, Aliberti J, King LR, Manischewitz J, Andersen J, Valenzuela J, Landau NR, Sher A (2003) Inhibition of HIV infection by a CCR5 binding cyclophilin from Toxoplasma gondii. Blood 102:3280-3286
215. Murphy PM (2001) Viral exploitation and subversion of the immune system through chemokine mimicry. Nat Immunol 2:116-122
216. Lim K, Glass WG, McDermott DH, Murphy PM (2006) CCR5: no longer a "good for nothing" gene-chemokine control of the West Nile virus infection. Trends Immunol 27:308-312
217. Seet B, McFadden G (2002) Viral chemokine-binding proteins. J Leukoc Biol 72:24-34
218. Webb LM, Alcami A (2005) Virally encoded chemokine binding proteins. Mini Rev Med Chem 5:833-848
219. Alexander JM, Nelson CA, van Berkel V, Lau EK, Studts JM, Brett J, Speck SH, Handel TM, Virgin HW, Fremont DH (2002) Structural basis of chemokine sequestration by a herpesvirus decoy receptor. Cell 111:343-356
220. Liu L, Dai E, Miller L, Seet B, Lalani A, Macauley C, Li X, Virgin HW, Bunce C, Turner P, Moyer R, McFadden G, Lucas A (2004) Viral chemokine binding proteins inhibit inflammatory responses and aortic allograft transplant vasculopathy in rat models. Transplantation 77:1653-1660
221. Alejo A, Ruiz-Argüello MB, Ho Y, Smith VP, Saraiva M, Alcami A (2006) A chemokine binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. Proc Natl Acad Sci USA 103:5995-6000
222. Smith P, Fallon RE, Mangan NE, Walsh CM, Saraiva M, Sayers JR, McKenzie AN, Alcami A, Fallon PG (2005) Schistosoma mansoni secretes a chemokine binding protein with antiinflammatory activity. J Exp Med 202:1319-1335
223. Kocáková P, Sláviková M, Hajnická V, Slovák M, Gasperík J, Vancová I, Fuchsberger N, Nuttall PA (2003) Effect of fast protein liquid chromatography fractionated salivary gland extracts from different ixodic tick species on interleukin-8 binding to its cell receptors. Folia Parasitol (Praha) 50:79-84
224. Oliveira CJF, Cavassani KA, Moré DD, Garlet GP, Aliberti JC, Silva JS, Ferreira BR (2008) Tick saliva inhibits the chemotactic function of MIP-1a and selectively impairs chemotaxis of immature dendritic cells by down-regulating cell-surface CCR5. Int J Parasitol 38:705-716
225. Frauenschuh A, Power CA, Déruaz M, Ferreira BR, Silva JS, Teixeira MM, Dias JM, Martin T, Wells TNC, Proudfoot AEI (2007) Molecular cloning and characterization of a hihgly selective chemokine-binding protein from zhe tick Rhipicephalus sanguineus. J Biol Chem 282:27250-27258
226. Déruaz M, Frauenschuh A, Alessandri AL, Dias JM, Coelho FM, Russo RC, Ferreira BR, Graham GJ, Shaw JP, Wells TNC, Teixeira MM, Power CA, Proudfoor AEI (2008) Ticks produce highly selective chemokine binding proteins with antiinflammatory activity. J Exp Med 205:2019-2031